Previous Article | Next Article ![]()
Infection and Immunity, March 2004, p. 1828-1831, Vol. 72, No. 3
0019-9567/04/$08.00+0 DOI: 10.1128/IAI.72.3.1828-1831.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Biochemical Pharmacology, University of Konstanz, 78457 Konstanz,1 Institute for Microbiology and Hygiene, University Medical Center Charité, 10117 Berlin, Germany,2 Department of Medicine, Section of Molecular Medicine and Infectious Diseases, Wake Forest University Health Sciences, Winston-Salem, North Carolina 27157-10423
Received 13 August 2003/ Returned for modification 24 September 2003/ Accepted 19 November 2003
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
A mutation screen of 110 healthy volunteers found only one missense mutation of tlr2 (Arg753Gln) in the open reading frame (5). Functional studies of that polymorphism in transfected cells showed a diminished response to peptides derived from Borrelia burgdorferi and Treponema pallidum; however, the incidence of the polymorphism was not higher in a septic-shock population than in healthy volunteers (5). The immunostimulatory principles of borreliae and treponemata are not yet clearly defined. We have developed an isolation procedure for lipoteichoic acid (LTA) from gram-positive bacteria which yields highly pure, bioactive LTA (6) that requires TLR2 for signaling (3). LTA from Staphylococcus aureus was synthesized chemically on the basis of the proposed structure and found to have biological activity comparable to that of purified natural LTA (8). Thus, we employed LTA from S. aureus, Bacillus subtilis, and live S. aureus to investigate the influence of the Arg753Gln TLR2 polymorphism on inflammatory capacity.
293T cells transfected with wild-type TLR2 as previously described (5) responded to stimulation with LTA from S. aureus (6 h at 1.5 µg/ml) with increased NF-
B-luciferase reporter activity (Fig. 1). This significant increase above basal activity was absent in cells transfected with the Arg753Gln polymorphism, indicating that the polymorphism results in a nonfunctional protein.
|
) as 10 µg of LTA/ml did, as measured by an enzyme-linked immunosorbent assay (ELISA) after overnight incubation of 20% whole blood performed as previously described (10) (Fig. 2). All LPS, when calibrated to TNF-
release, also induced the release of uniform amounts of the other mediators measured, indicating a common activation pattern of LPS in general. LTA, in comparison to these LPS, did not induce measurable gamma interferon (IFN-
) (data not shown), as expected on the basis of an earlier study (2), but induced significantly higher levels of the anti-inflammatory cytokines granulocyte colony-stimulating factor (G-CSF) and interleukin-10 (IL-10) and of the chemokines (Fig. 2). There are not yet any clear indications in the literature of how the signal transduction pathways differ between LPS and LTA apart from the use of different TLRs, i.e., TLR4 for LPS and TLR2 for LTA (3). The data discussed here strongly indicate that the pathways do not simply converge, and these data demand further investigation. It is tempting to correlate the pronounced induction of IL-8 and G-CSF, both involved in neutrophil attraction and recruitment, by LTA with the well-known pus formation typical for many gram-positive infections. From these data, the cytokines TNF-
, IFN-
, IL-8, and IL-10 were chosen to represent the overall cytokine pattern induced by the two different stimuli.
|
and IFN-
, the chemokine IL-8, and the anti-inflammatory cytokine IL-10 released were measured. As shown in Fig. 3, the subjects with the heterozygous polymorphism responded to LTA from B. subtilis with sensitivities and quantities of cytokine release similar to those of the wild-type subjects. Furthermore, the cytokine responses of the two groups to LTA from S. aureus, live S. aureus, or PMA were not significantly different for any parameter measured (Table 1). The batch of LTA from S. aureus employed in these experiments was less potent in inducing cytokine responses than the B. subtilis preparation. However, the lower potency of S. aureus LTA represents no general phenomenon.
|
|
induction levels, showing that LTA is not just a weaker endotoxin but also a potent stimulus in its own right. The transfection results presented here show that the TLR2 polymorphism at position 753 is a functional knockout of LTA stimulation, similar to the TLR4 polymorphism at position 299 for LPS. However, the inflammatory response of heterozygous carriers of the polymorphism to TLR2 agonists was not different from that of wild-type controls, indicating that one allele carrying a nonfunctional TLR2 polymorphism is compensated by the second allele. These data complement previous studies on the TLR4 polymorphism, which found no difference in the responses to LPS in the blood of heterozygous donors and even one homozygous donor (1, 10). Polymorphisms in the TLRs do not appear to be responsible for differences in cytokine responses or, by extrapolation, vulnerability to bacterial infections.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
| 1. | Erridge, C., J. Stewart, and I. R. Poxton. 2003. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J. Exp. Med. 197:1787-1791. |
| 2. | Hermann, C., I. Spreitzer, N. W. Schroder, S. Morath, M. D. Lehner, W. Fischer, C. Schutt, R. R. Schumann, and T. Hartung. 2002. Cytokine induction by purified lipoteichoic acids from various bacterial speciesrole of LBP, sCD14, CD14 and failure to induce IL-12 and subsequent IFN-gamma release. Eur. J. Immunol. 32:541-551.[CrossRef][Medline] |
| 3. | Lehner, M. D., S. Morath, K. S. Michelsen, R. R. Schumann, and T. Hartung. 2001. Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators. J. Immunol. 166:5161-5167. |
| 4. | Lien, E., and R. R. Ingalls. 2002. Toll-like receptors. Crit. Care Med. 30:S1-S11.[CrossRef][Medline] |
| 5. | Lorenz, E., J. P. Mira, K. L. Cornish, N. C. Arbour, and D. A. Schwartz. 2000. A novel polymorphism in the Toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect. Immun. 68:6398-6401. |
| 6. | Morath, S., A. Geyer, and T. Hartung. 2001. Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J. Exp. Med. 193:393-397. |
| 7. | Morath, S., A. Geyer, I. Spreitzer, C. Hermann, and T. Hartung. 2002. Structural decomposition and heterogeneity of commercial lipoteichoic acid preparations. Infect. Immun. 70:938-944. |
| 8. | Morath, S., A. Stadelmaier, A. Geyer, R. R. Schmidt, and T. Hartung. 2002. Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release. J. Exp. Med. 195:1635-1640. |
| 9. | Schröder, N. W., C. Hermann, L. Hamann, U. B. Gobel, T. Hartung, and R. R. Schumann. 2003. High frequency of polymorphism Arg753Gln of the Toll-like receptor-2 gene detected by a novel allele-specific PCR. J. Mol. Med. 81:368-372.[Medline] |
| 10. | von Aulock, S., N. W. Schröder, K. Gueinzius, S. Traub, S. Hoffmann, K. Graf, S. Dimmeler, T. Hartung, R. R. Schumann, and C. Hermann. 2003. Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J. Infect. Dis. 188:938-943.[CrossRef][Medline] |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|